Imrecoxib NEW
| Price | $29 | Get Latest Price |
| Package | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-05 |
Product Details
| Product Name: Imrecoxib | CAS No.: 395683-14-4 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2025/12/05 |
Product Introduction
Bioactivity
| Name | Imrecoxib |
| Description | Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor (IC50: 18 nM) that also inhibits COX-1 activity (IC50: 115 nM) and exhibits anti-inflammatory effects. |
| In vitro | In U937 cells, Imrecoxib (0.1-10 μM; 24 hours) reduces COX-2 mRNA level induced by PMA+LPS in a dose-dependent manner. |
| In vivo | Imrecoxib (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling. It also inhibits heat-inactivated BCG induced-inflammtory polyarthritis. Imrecoxib (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) suppresses carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (8.93 mM), Sonication is recommended. DMSO : 90 mg/mL (243.59 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | Imrecoxib | Human COX-2 | Human COX-1 | Cyclooxygenase | COX-2 | COX-1 | COX | BAP909 | BAP 909 |
| Inhibitors Related | Acetaminophen | Phenidone | Deferiprone | 4-Aminosalicylic acid | Gallic Acid Monohydrate | Diclofenac Potassium | Paradol | Trometamol | 5-Methylfurfural | Phenylbutazone | Revaprazan hydrochloride | Magnesium sulfate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Approved Drug Library | Neuronal Signaling Compound Library | HIF-1 Signaling Pathway Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-07-08 | |
| $0.00/25kg |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-06-12 | |
| $1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2021-06-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY